You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Atezolizumab

Showing 526 - 550 of 765
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in United States (Atezolizumab)

Unknown status
  • Carcinoma, Non-Small-Cell Lung
  • Atezolizumab
  • Phoenix, Arizona
  • +12 more
Feb 10, 2020

Breast Cancer, Renal Cell Carcinoma Trial in United States (IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel)

Active, not recruiting
  • Breast Cancer
  • Renal Cell Carcinoma
  • IPI-549 (eganelisib)
  • +3 more
  • Chandler, Arizona
  • +23 more
Apr 1, 2022

NSCLC Trial in Worldwide (Alectinib, Atezolizumab, Erlotinib)

Completed
  • Non-Small Cell Lung Cancer
  • Orange, California
  • +16 more
Apr 17, 2020

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Melbourne (Atezolizumab, Bevacizumab, Cobimetinib)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Atezolizumab
  • +2 more
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Dec 18, 2019

NSCLC (NSCLC) Trial in Worldwide (Atezolizumab, Tiragolumab, Durvalumab)

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Atezolizumab
  • +2 more
  • Tempe, Arizona
  • +254 more
Aug 8, 2022

Metastatic Prostate Cancer, Prostate Adenocarcinoma Trial in Worldwide (Cabozantinib, Atezolizumab, Abiraterone Acetate)

Recruiting
  • Metastatic Prostate Cancer
  • Prostate Adenocarcinoma
  • Tucson, Arizona
  • +259 more
Oct 19, 2022

Melanoma, Head Neck Cancer, Sarcoma Trial in United States (Hiltonol)

Completed
  • Melanoma
  • +3 more
  • Hiltonol
  • Chevy Chase, Maryland
  • +4 more
Dec 15, 2020

Squamous NSCLC Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody,

Completed
Has Results
  • Squamous Non-Small Cell Lung Cancer
  • Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
  • +3 more
  • Chandler, Arizona
  • +241 more
Mar 17, 2022

Muscle-invasive Bladder Cancer Trial in Worldwide (Atezolizumab, Placebo)

Recruiting
  • Muscle-invasive Bladder Cancer
  • Atezolizumab
  • Placebo
  • Santa Barbara, California
  • +167 more
Mar 17, 2022

Rare Tumor Trial (Almonertinib 110 MG, Dacomitinib 45 MG, Alectinib 150 MG)

Not yet recruiting
  • Rare Tumor
  • Almonertinib 110 MG
  • +10 more
  • (no location specified)
Jul 31, 2020

Renal Cell Carcinoma Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Sunitinib)

Completed
Has Results
  • Renal Cell Carcinoma
  • Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
  • +2 more
  • Tucson, Arizona
  • +153 more
Jan 13, 2022

Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8 Trial in Japan, United

Recruiting
  • Limited Stage Lung Small Cell Carcinoma
  • +12 more
  • 3-Dimensional Conformal Radiation Therapy
  • +7 more
  • Birmingham, Alabama
  • +544 more
Aug 24, 2022

AImmune - Artificial Intelligence Algorithm for Identification

Unknown status
  • Non Small Cell Lung Cancer
  • +5 more
  • Collection of biopsy (FFPE), blood (PBMC) and stool
  • Gdańsk, Poland
    University Clinical Centre in Gdansk
Aug 7, 2020

Hodgkin Lymphoma Trial in United States (Atezolizumab)

Terminated
Has Results
  • Hodgkin Lymphoma
  • Atezolizumab
  • Basking Ridge, New Jersey
  • +5 more
Nov 12, 2019

Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma Trial in Belgium (Nivolumab or Pembrolizumab or Atezolizumab, SBRT)

Active, not recruiting
  • Urothelial Carcinoma
  • +4 more
  • Nivolumab or Pembrolizumab or Atezolizumab
  • SBRT
  • Ghent, Oost-Vlaanderen, Belgium
  • +4 more
Oct 30, 2020

NSCLC Trial in Worldwide (Atezolizumab, Daratumumab)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Loma Linda, California
  • +46 more
Nov 5, 2019

Response in Patients Treated by Immunotherapy for Advanced

Not yet recruiting
  • Hepatocellular Carcinoma
  • patients with hepatocellular carcinoma
  • (no location specified)
Jan 28, 2022

Metastatic Colorectal Cancer Trial in Worldwide (Inavolisib, Bevacizumab, Cetuximab)

Recruiting
  • Metastatic Colorectal Cancer
  • Birmingham, Alabama
  • +36 more
Dec 29, 2022

Carcinoma, Non-Squamous Non-Small Cell Lung Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody,

Completed
Has Results
  • Carcinoma, Non-Squamous Non-Small Cell Lung
  • Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
  • +3 more
  • Springdale, Arkansas
  • +131 more
Jul 15, 2021

HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer Trial in

Completed
  • HER2-Positive Metastatic Breast Cancer
  • +2 more
  • Atezolizumab
  • +7 more
  • Birmingham, Alabama
  • +19 more
Jan 31, 2020

Non Small Cell Lung Cancer Trial in Detroit (drug, diagnostic test, other)

Unknown status
  • Non Small Cell Lung Cancer
  • Detroit, Michigan
    Henry Ford Health Systems
Mar 25, 2020

Breast Cancer Trial in Worldwide (Atezolizumab, Trastuzumab Emtansine, Placebo)

Recruiting
  • Breast Cancer
  • Atezolizumab
  • +3 more
  • Alabaster, Alabama
  • +305 more
Jan 10, 2023

NSCLC Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Carboplatin)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
  • +3 more
  • Chandler, Arizona
  • +239 more
Aug 26, 2021

Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Tumor Trial in Houston (biological,

Recruiting
  • Advanced Bladder Carcinoma
  • +34 more
  • Atezolizumab
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Cancer, Tumors, Tumor Trial in Netherlands (Panitumumab, Olaparib, Dabrafenib)

Recruiting
  • Cancer
  • +3 more
  • Amersfoort, Utrecht, Netherlands
  • +34 more
Oct 26, 2021